REFLECT real-world evidence (RWE) prospective study update: Efficacy and safety results of Sandoz biosimilar rituximab (SDZ-RTX) for the treatment of diffuse large B-cell lymphoma (DLBCL). 13. Juli 2020 Welslau M, Marschner N, Otremba B, Topaly J, Bittencourt da Silva L, 2020. J Clin Oncol 38 no. 15_suppl (May 20, 2020) 8060-8060. DOI: 10.1200/JCO.2020.38.15_suppl.8060 Real-world effectiveness of nab-paclitaxel plus carboplatin as first-line therapy for patients with advanced NSCLC: Results of the second interim analysis of the NEPTUN study. Dechow T, Riera-Knorrenschild J, Hackanson B, Fischer von Weikersthal L, Schulz H, Chiabudini M, Timm B, Zerbes R, Potthoff K, 2020. J Clin Oncol 38:… Weiterlesen REFLECT real-world evidence (RWE) prospective study update: Efficacy and safety results of Sandoz biosimilar rituximab (SDZ-RTX) for the treatment of diffuse large B-cell lymphoma (DLBCL). Welslau M, Marschner N, Otremba B, Topaly J, Bittencourt da Silva L, 2020. HemaSphere 4(S1) (EP1245), 583. Weiterlesen